Scott M. Plesha - 27 Jan 2022 Form 4 Insider Report for BIODELIVERY SCIENCES INTERNATIONAL INC

Role
President and Chief Commercial Officer
Signature
/s/ Scott Plesha
Issuer symbol
N/A
Transactions as of
27 Jan 2022
Net transactions value
+$1,353,179
Form type
4
Filing time
31 Jan 2022, 16:56:06 UTC
Next filing
22 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDSI Common Stock Options Exercise $0 +21,050 +7% $0.000000 320,924 27 Jan 2022 Direct
transaction BDSI Common Stock Options Exercise $0 +10,869 +3.4% $0.000000 331,793 31 Jan 2022 Direct
transaction BDSI Common Stock Options Exercise $0 +13,334 +4% $0.000000 345,127 31 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSI Stock Options (right to buy) Award $1,353,179 +369,721 $3.66 369,721 27 Jan 2022 Common Stock 369,721 $3.66 Direct F1, F2
transaction BDSI Restricted Stock Units Award $0 +66,257 $0.000000 66,257 27 Jan 2022 Common Stock 66,257 $0.000000 Direct F3, F4
transaction BDSI Restricted Stock Units Options Exercise $0 -21,050 -33% $0.000000 42,101 27 Jan 2022 Common Stock 21,050 $0.000000 Direct F5
transaction BDSI Restricted Stock Units Options Exercise $0 -10,869 -50% $0.000000 10,870 29 Jan 2022 Common Stock 10,869 $0.000000 Direct F6
transaction BDSI Restricted Stock Units Options Exercise $0 -13,334 -100% $0.000000* 0 31 Jan 2022 Common Stock 13,334 $0.000000 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.
F2 The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
F3 The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
F4 Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
F5 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs will vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024.
F6 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Plan. The remaining RSUs vest on January 29, 2023.
F7 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan.

Remarks:

President and Chief Commercial Officer